Intravenous Iron Isomaltoside for Patients with Iron Deficiency Undergoing Elective Surgery


( Last Updated : October 28, 2022)
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1456-000
Effective finish date:

Details


Question

  1. What is the clinical effectiveness of IV iron isomaltoside for patients identified as iron deficient undergoing elective surgery, including high blood loss surgery?

Key Message

The results of 1 randomized controlled trial did not find a difference in functional status (6-minute walk distance and New York Heart Association class), hand grip strength, or health-related quality of life for patients who underwent a transcatheter aortic valve implantation treated with iron isomaltoside versus placebo.

There was 1 (1.4%) hypersensitivity reaction and 1 (1.4%) episode of chest pain in patients treated with iron isomaltoside in the randomized controlled trial. Rates of other adverse events were similar between patients treated with iron isomaltoside and placebo.